Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study
Authors
Hutchings, MartinRadford, John A
Ansell, S. M.
Illés, Árpád
Sureda, Anna
Connors, J. M.
Sýkorová, Alice
Shibayama, Hirohiko
Abramson, Jeremy S
Chua, Neil
Friedberg, Jonathan W
Kořen, Jan
LaCasce, Ann Steward
Molina, Lysiane
Engley, Gerald
Fenton, K.
Jolin, Hina
Liu, Rachael
Gautam, Ashish
Gallamini, Andrea
Affiliation
Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, DenmarkIssue Date
2021-04
Metadata
Show full item recordAbstract
Approximately one-third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high-risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4-7, enrolled in the ECHELON-1 study that compared brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as first-line therapy after a median follow-up of 37.1 months. Among patients treated with A + AVD (n = 664) or ABVD (n = 670), 64% had Stage IV disease and 26% had an IPS of 4-7. Patients with Stage IV disease treated with A + AVD showed consistent improvements in PFS at 3 years as assessed by investigator (hazard ratio [HR], 0.723; 95% confidence interval [CI], 0.537-0.973; p = 0.032). Similar improvements were seen in the subgroup of patients with IPS of 4-7 (HR, 0.588; 95% CI, 0.386-0.894; p = 0.012). The most common adverse events (AEs) in A + AVD-treated versus ABVD-treated patients with Stage IV disease were peripheral neuropathy (67% vs. 40%) and neutropenia (71% vs. 55%); in patients with IPS of 4-7, the most common AEs were peripheral neuropathy (69% vs. 45%), neutropenia (66% vs. 55%), and febrile neutropenia (23% vs. 9%), respectively. Patients in high-risk subgroups did not experience greater AE incidence or severity than patients in the total population. This updated analysis of ECHELON-1 shows a favorable benefit-risk balance in high-risk patients.Citation
Hutchings, M, Radford, J, Ansell, S.M, Illés, Á, Sureda, Anna, Connors, J.M, et al. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological Oncology. 2021 Apr;39(2):185-195.Journal
Hematological OncologyDOI
10.1002/hon.2838PubMed ID
33462822Additional Links
https://dx.doi.org/10.1002/hon.2838Type
ArticleLanguage
enISSN
0278-0232EISSN
1099-1069ae974a485f413a2113503eed53cd6c53
10.1002/hon.2838